Adding perioperative pembrolizumab to standard care can improve EFS in locally advanced head and neck cancer, data suggest.

Results from phase 2 trials appear to support the use of chemotherapy-free regimens in patients with osimertinib-resistant NSCLC.

Using both liquid and tissue biopsies to guide targeted treatment may improve outcomes in patients with solid tumor malignancies.

New research suggests that a ctDNA assay can detect colorectal cancer recurrence months before it is detected via imaging.

Tumor-infiltrating clonal hematopoiesis was associated with a greater risk of recurrence or death in patients with non-small-cell lung cancer.

Induction chemotherapy followed by IMRT is noninferior to CCRT for locoregionally advanced nasopharyngeal carcinoma, data suggest.

Researchers found that colibactin-induced mutational signatures were enriched in early-onset colorectal cancer cases.

Infection is a common cause of death in the first year after diagnosis with lower-risk myelodysplastic syndromes, data suggest.

Tepylute is now supplied as a multiple-dose vial containing 100 mg of thiotepa in addition to the previously approved single-dose vial containing 15 mg.

The FDA has issued a complete response letter to Telix Pharmaceuticals regarding TLX101-CDx for the imaging of gliomas.

Dostarlimab may eliminate the need for surgery in certain patients with dMMR solid tumor malignancies, a phase 2 study suggests.

Having detectable ctDNA before treatment is associated with worse outcomes among patients with mCRPC, regardless of the treatment they receive.